Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24941981 | 0.86 | OPRL1 (0.43) | OPRL1OPRM1OPRK1HRH3 | |
| SCHEMBL27131232 | 0.85 | MEN1 (0.42) | TSHRHRH3 | |
| SCHEMBL25046319 | 0.85 | MEN1 (0.42) | TSHRHRH3 | |
| SCHEMBL10092700 | 0.82 | HRH3 (0.41) | TSHRHRH3 | |
| SCHEMBL178288 | 0.81 | HRH3 (0.46) | HRH3 | |
| SCHEMBL10648639 | 0.81 | OPRL1 (0.53) | OPRL1OPRM1OPRK1HRH3 | |
| SCHEMBL10648643 | 0.81 | OPRL1 (0.53) | OPRL1OPRM1OPRK1HRH3 | |
| SCHEMBL21934638 | 0.80 | HRH3 (0.35) | TSHRHRH3 | |
| SCHEMBL8278983 | 0.78 | OPRL1 (0.50) | OPRL1OPRM1OPRK1HRH3 | |
| SCHEMBL7215234 | 0.77 | OPRL1 (0.50) | OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | OPRL1 4314/4885OPRM1 4659/4885OPRK1 4398/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | OPRL1 4314/4885OPRM1 4659/4885OPRK1 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.